Virginia D. Steen
#121,528
Most Influential Person Now
Virginia D. Steen's AcademicInfluence.com Rankings
Virginia D. Steenmedical Degrees
Medical
#1865
World Rank
#2244
Historical Rank
Rheumatology
#12
World Rank
#13
Historical Rank
Download Badge
Medical
Why Is Virginia D. Steen Influential?
(Suggest an Edit or Addition)Virginia D. Steen's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. (2013) (2731)
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative (2013) (1713)
- Changes in causes of death in systemic sclerosis, 1972–2002 (2007) (1305)
- Cyclophosphamide versus placebo in scleroderma lung disease. (2006) (1176)
- Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. (2004) (924)
- Severe organ involvement in systemic sclerosis with diffuse scleroderma. (2000) (876)
- Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. (1988) (571)
- Severe restrictive lung disease in systemic sclerosis. (1994) (515)
- Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. (2003) (496)
- Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial (2016) (479)
- Autoantibodies in systemic sclerosis. (1996) (457)
- Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. (1993) (455)
- The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. (1997) (437)
- A disease severity scale for systemic sclerosis: development and testing. (1999) (436)
- Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial (2016) (429)
- Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. (2007) (418)
- Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. (1998) (417)
- Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. (1990) (415)
- Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study (1994) (379)
- Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. (1986) (373)
- High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. (1999) (307)
- D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. (1982) (304)
- Long-Term Outcomes of Scleroderma Renal Crisis (2000) (288)
- The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. (1998) (284)
- Autoantibodies in systemic sclerosis. (1996) (278)
- Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. (2000) (272)
- Recombinant Human Relaxin in the Treatment of Scleroderma (2000) (267)
- The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. (1991) (266)
- Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis (2017) (264)
- Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. (1984) (252)
- Isolated diffusing capacity reduction in systemic sclerosis. (1992) (237)
- 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases (2020) (236)
- Improvement in skin thickening in systemic sclerosis associated with improved survival. (2001) (231)
- Digital ulcers: overt vascular disease in systemic sclerosis. (2006) (227)
- Factors predicting development of renal involvement in progressive systemic sclerosis. (1984) (221)
- Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. (1984) (220)
- Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. (2002) (220)
- Autoantibody Reactive with RNA Polymerase III in Systemic Sclerosis (1993) (212)
- Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. (1990) (211)
- Normotensive renal failure in systemic sclerosis. (1989) (207)
- Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate) (2017) (204)
- Scleroderma renal crisis. (1996) (203)
- Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). (1988) (197)
- Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. (1994) (189)
- Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report (2019) (181)
- Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. (1992) (178)
- Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. (2014) (177)
- A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. (2003) (176)
- Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. (1997) (174)
- Pulmonary involvement in systemic sclerosis (scleroderma). (1985) (174)
- Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. (2006) (162)
- Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. (2005) (153)
- Pregnancy in women with systemic sclerosis. (1999) (153)
- Anti-SS-A antibodies and fetal outcome in maternal systemic lupus erythematosus. (1986) (146)
- Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. (2008) (144)
- Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. (2006) (142)
- Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study (2006) (141)
- Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (2014) (137)
- Prognostic importance of cardiac arrhythmias in systemic sclerosis. (1988) (135)
- A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. (2012) (133)
- Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. (1983) (133)
- Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial (2020) (132)
- Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. (2005) (130)
- Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. (2009) (129)
- Predictors of end stage lung disease in systemic sclerosis (2003) (128)
- Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. (2007) (127)
- Pulmonary complications: one of the most challenging complications of systemic sclerosis. (2006) (124)
- Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. (2011) (118)
- Epidemiology and natural history of systemic sclerosis. (1990) (115)
- Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. (1999) (115)
- Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts (2018) (114)
- Fertility and pregnancy outcome in women with systemic sclerosis. (1999) (112)
- Kidney disease other than renal crisis in patients with diffuse scleroderma. (2005) (107)
- Cutaneous hypoxia in patients with systemic sclerosis (scleroderma). (1988) (107)
- Scleroderma renal crisis. (1996) (106)
- The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. (2001) (105)
- MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. (2009) (104)
- Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials (2013) (104)
- Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. (2007) (102)
- Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. (1985) (101)
- The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. (1985) (97)
- Early Undifferentiated Connective Tissue Disease: III. Outcome and Prognostic Indicators in Early Scleroderma (Systemic Sclerosis) (1993) (93)
- Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management (2012) (93)
- A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. (2008) (92)
- Systemic sclerosis - continuing progress in developing clinical measures of response. (2007) (90)
- Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry (2012) (87)
- Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population (2011) (87)
- The effect of D-penicillamine on pulmonary findings in systemic sclerosis. (1985) (85)
- Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis (2007) (84)
- The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. (1997) (83)
- Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. (2009) (83)
- The palpable tendon friction rub (1997) (83)
- Gastric Antral Vascular Ectasia in Systemic Sclerosis: Demographics and Disease Predictors (2010) (82)
- Skin thickness score in systemic sclerosis (1993) (82)
- Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. (1988) (82)
- Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile (2019) (81)
- Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. (1996) (81)
- Clinical manifestations of systemic sclerosis. (1998) (81)
- Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study (2014) (79)
- Treatment of systemic sclerosis with recombinant interferon‐γ. A phase I/II clinical trial (1992) (78)
- Pregnancy in women with systemic sclerosis. (1989) (76)
- Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. (2014) (76)
- The toxicity of D-penicillamine in systemic sclerosis. (1986) (75)
- Assessment of kidney involvement. (2003) (75)
- Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. (1996) (73)
- Pregnancy in scleroderma. (2007) (72)
- 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases (2020) (71)
- Surgery for scleroderma of the hand. (1987) (71)
- The lung in systemic sclerosis. (2005) (67)
- Long‐Term Outcomes in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS) (2018) (67)
- Renal involvement in systemic sclerosis. (1994) (66)
- Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. (1989) (66)
- Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. (2014) (62)
- Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. (2007) (61)
- The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (2016) (60)
- Vasculitis in systemic sclerosis: association with Sjögren's syndrome and the CREST syndrome variant. (1987) (60)
- Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise (2012) (60)
- The heart in systemic sclerosis (2004) (58)
- Antinuclear antibody-negative systemic sclerosis. (2015) (58)
- Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis (2014) (55)
- Lower Extremity Ulcers in Systemic Sclerosis: Features and Response to Therapy (2010) (53)
- Renal Manifestations in Scleroderma: Evidence for Subclinical Renal Disease as a Marker of Vasculopathy (2010) (53)
- High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. (2004) (53)
- Small fiber neuropathy and vasculitis. (1997) (51)
- Myocardial function and perfusion in the CREST syndrome variant of progressive systemic sclerosis. Exercise radionuclide evaluation and comparison with diffuse scleroderma. (1984) (51)
- Comparative studies of esophageal function in systemic sclerosis. (1992) (51)
- Clinical and serological features of systemic sclerosis in a multicenter African American cohort (2017) (49)
- Factors Predicting Development of Renal Involvement in Progressive Systemic Sclerosis (1984) (48)
- Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial (2020) (48)
- Registries in systemic sclerosis: a worldwide experience. (2011) (46)
- Kidney involvement in systemic sclerosis. (2014) (46)
- Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis (2011) (46)
- Scleroderma and pregnancy. (1997) (45)
- Advancements in diagnosis of pulmonary arterial hypertension in scleroderma. (2005) (44)
- Scleroderma renal crisis. (2007) (44)
- Systemic sclerosis (scleroderma) (1991) (42)
- Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. (1985) (42)
- 2019 American College of Rheumatology Reproductive Health in Rheumatic and Musculoskeletal Diseases Guideline. (2020) (42)
- The many faces of scleroderma. (2008) (42)
- Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS) (2009) (42)
- Soluble serum interleukin 2 receptors in patients with systemic sclerosis. (1996) (42)
- Practical approach to screening for scleroderma‐associated pulmonary arterial hypertension (2012) (41)
- Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease–Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities (2019) (40)
- HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry (2019) (38)
- Treatment of early diffuse systemic sclerosis skin disease. (2013) (38)
- Factors related to oral hygiene in persons with scleroderma. (2005) (38)
- The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (2016) (36)
- Clinical trials in systemic sclerosis: lessons learned and outcomes (2007) (34)
- Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology (2019) (33)
- Scleroderma Mimics (2011) (33)
- Increased Morbidity and Mortality of Scleroderma in African Americans Compared to Non–African Americans (2019) (33)
- Optimal management of digital ulcers in systemic sclerosis (2015) (33)
- The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts (2018) (32)
- Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study (2010) (32)
- Oral hygiene in scleroderma: The effectiveness of a multi-disciplinary intervention program (2010) (32)
- Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis (2020) (28)
- Pregnancy outcomes in women with primary Raynaud's phenomenon. (2010) (27)
- Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study (2017) (27)
- Role of anti-receptor autoantibodies in pathophysiology of scleroderma. (2017) (26)
- Lower extremity ulcers in connective tissue disease. (2008) (25)
- Lower extremity amputation in scleroderma. (1992) (23)
- Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego, Shortness of Breath Questionnaire (2013) (23)
- Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up (2017) (23)
- Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study (2020) (23)
- Phenothiazine-induced systemic lupus erythematosus with superior vena cava syndrome: case report and review of the literature. (1988) (23)
- Study of 102 Consecutive Cases with Functional Correlations and Review of the Literature (1985) (23)
- Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis–Related Pulmonary Arterial Hypertension (2015) (22)
- Combination of Echocardiographic and Pulmonary Function Test Measures Improves Sensitivity for Diagnosis of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: Analysis of 2 Cohorts (2013) (22)
- Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. (2020) (20)
- Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. (2017) (20)
- Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations (2018) (20)
- Quality indicator set for systemic sclerosis. (2011) (20)
- 1972-2002in causes of death in systemic sclerosis, (2007) (20)
- Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial. (1992) (20)
- Treatment of systemic sclerosis. (1991) (19)
- Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry (2018) (19)
- Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report (2018) (19)
- Therapy for Pulmonary Arterial Hypertension in Adults (2019) (19)
- Reduced natural killer cell activity in patients with systemic sclerosis. Correlation with clinical disease type. (1988) (18)
- Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States. (2011) (18)
- Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients (2020) (18)
- The use of an elevated aldolase in diagnosing and managing eosinophilic fasciitis (2015) (18)
- Targeted therapy for systemic sclerosis. (2006) (17)
- A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers (2019) (17)
- Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. (2015) (17)
- Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort (2021) (16)
- Occupational scleroderma. (1999) (15)
- Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients (2016) (15)
- The Recurrence of Digital Ulcers in Patients with Systemic Sclerosis after Discontinuation of Oral Treprostinil (2016) (15)
- Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease (2020) (15)
- Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial. (2001) (14)
- Treatment of Systemic Sclerosis (1991) (14)
- Voriconazole-associated myositis. (2009) (13)
- A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. (2021) (13)
- Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort (2017) (13)
- Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. (2020) (12)
- Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis–Associated Pulmonary Arterial Hypertension (2019) (12)
- Overall mortality (2020) (12)
- Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis (2018) (12)
- Cross-cultural adaptation and validation of the Brazilian version of the Scleroderma Health Assessment Questionnaire (SHAQ) (2013) (12)
- Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. (2015) (11)
- Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer (2018) (11)
- African American race associated with body image dissatisfaction among patients with systemic sclerosis. (2016) (11)
- Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report (2015) (10)
- Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score (2021) (10)
- Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. (2020) (10)
- Management of Renal Involvement in Scleroderma (2015) (10)
- Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort (2018) (10)
- Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), and the Potential Future Role of Anti-fibrotics[asterisk] in a Treatment Paradigm for SSc-ILD: A Delphi Consensus Study (2019) (9)
- Brief Report: Whole‐Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans (2018) (9)
- Compression of the median nerve proximal to the carpal tunnel in scleroderma. (1996) (9)
- Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry (2019) (8)
- Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients (2020) (8)
- Patient and Physician Perspectives on Systemic Sclerosis–Associated Interstitial Lung Disease (2020) (8)
- MQX-503, a novel topical nitroglycerin formulation, improves severity of symptoms associated with Raynaud's phenomenon (2008) (7)
- Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort (2017) (7)
- Vascular Disease in Systemic Sclerosis (2010) (7)
- Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes (2020) (7)
- Scleroderma Renal Crisis. (2020) (7)
- Racial Disparities in Systemic Sclerosis. (2020) (7)
- Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study (2020) (7)
- SYSTEMIC SCLEROSIS RELATED CALCINOSIS: PATIENTS PROVIDE WHAT SPECIALISTS WANT TO LEARN. (2015) (7)
- A Novel Utility to Correct for Plate/Batch/Lot and Nonspecific Binding Artifacts in Luminex Data (2020) (6)
- Is exercise‐induced pulmonary hypertension ready for prime time in systemic sclerosis? (2011) (6)
- Pregnancy in systemic sclerosis. (1998) (6)
- D-penicillamine treatment in systemic sclerosis. (1991) (6)
- Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. (2021) (6)
- Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. (2016) (6)
- OP0249 LONG-TERM EXTENSION RESULTS OF RISE-SSC, A RANDOMIZED TRIAL OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC) (2020) (5)
- Expert consensus on the management of systemic sclerosis-associated interstitial lung disease (2023) (4)
- Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures? (2020) (4)
- Systemic Sclerosis Classification Criteria: Developing methods for multi-criteria decision analysis with 1000Minds (2014) (4)
- rheumatism collaborative initiative rheumatology / European league against sclerosis : an American college of 2013 classification criteria for systemic (2013) (4)
- The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial (2021) (3)
- Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. (2019) (3)
- Racial Disparities in Systemic Sclerosis: Short‐ and Long‐Term Outcomes Among African American Participants of SLS I and II (2020) (3)
- Successful Treatment of Pansclerotic Morphea with Imatinib Mesylate in a Pediatric Patient (2013) (3)
- Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study (2021) (3)
- Minimally Important Difference in Diffuse Systemic Sclerosis (2006) (3)
- A normal diffusing capacity of the lungs for carbon monoxide is rare in incidental pulmonary arterial hypertension in systemic sclerosis: Data from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma cohort (2018) (3)
- NHLBI Report: Impact of Sex and Gender on Autoimmune Lung Disease, Opportunities for Future Research. (2022) (3)
- THU0330 EFFECTS OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED ILD (SSC-ILD) AND DIFFERING EXTENTS OF SKIN FIBROSIS: FURTHER ANALYSES OF THE SENSCIS TRIAL (2020) (3)
- Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program (2022) (3)
- Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort. (2022) (2)
- Not all that is ‘full house’ is systemic lupus erythematosus: a case of membranous nephropathy due to syphilis infection (2021) (2)
- The pleomorphism of systemic sclerosis: are we ready for ‘personalized medicine’ in scleroderma? (2011) (2)
- PULMONARY HYPERTENSION ASSESSMENT AND RECOGNITION OF OUTCOMES IN SCLERODERMA (PHAROS): PATIENTS WITH PULMONARY HYPERTENSION (2009) (2)
- Cytokine signatures differentiate systemic sclerosis patients at high versus low risk for pulmonary arterial hypertension (2022) (2)
- Comparison of responders and non-responders to MQX-503, a novel investigational topical nitroglycerin formulation, in treatment of scieroderma-related and non-scleroderma-related Raynaud'S phenomenon (2008) (2)
- Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-risk Cohort of Patients with Systemic Sclerosis (2019) (2)
- Differential expression of hepatocyte growth factor in patients with systemic sclerosis-associated pulmonary arterial hypertension (2017) (2)
- FRI0575 BIOMARKER ANALYSIS FROM THE RISE-SSC STUDY OF RIOCIGUAT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC) (2020) (2)
- Systemic Sclerosis Associated Interstitial Lung Disease: A Conceptual Framework for Subclinical, Clinical, and Progressive Disease. (2022) (1)
- 144 – Management of systemic sclerosis (2015) (1)
- Systemic Sclerosis Mimics (2014) (1)
- Vasodilatory Therapeutics in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort (2012) (1)
- Reliance on Pulmonary Function Tests in Assessment of Systemic Sclerosis Patients for Pulmonary Hypertension: Comment on the Article by Antoniou et al (2017) (1)
- Safety and tolerability of MQX-503, a novel investigational topical formulation of nitroglycerin for the treatment of Raynaud's phenomenon (2008) (1)
- Safety and effi cacy of subcutaneous tocilizumab in adults with systemic sclerosis ( faSScinate ) : a phase 2 , randomised , controlled trial (2016) (1)
- Adipose-Derived Regenerative Cell Transplantation in Systemic Sclerosis: Scleroderma Treatment with Celution Processed Adipose Derived Regenerative Cells- a Randomized Clinical Trial. (2022) (1)
- Predictive Value Of Non-Invasive Tests For The Diagnosis Of Scleroderma-Associated Pulmonary Hypertension: Pharos Registry (2011) (1)
- A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials. (2022) (1)
- Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial (2022) (1)
- Detection Score for Pulmonary Hypertension in Systemic Sclerosis Patients: Observations from the Pharos Registry (2020) (1)
- Patient Experience of Systemic Sclerosis-Related Calcinosis: An International Study Informing Clinical Trials, Practice, and the Development of the Mawdsley Calcinosis Questionnaire. (2023) (1)
- Systemic Sclerosis (Scleroderma) and Raynaud’s Phenomenon (2009) (1)
- Challenges in management of a patient with oropharyngeal carcinoma and scleroderma (2020) (1)
- Interstitial Lung Disease in Systemic Sclerosis (2014) (1)
- FRI0475 Systemic Sclerosis (SSC) Related Calcinosis: Patients Provide what Specialists Want to Learn – Development of a Calcinosis Patient Reported Outcome Measure (PROM) (2015) (1)
- Pulmonary Hypertension Roundtable: PH and Connective Tissue Disease (2017) (0)
- Screening for PAH in Scleroderma: Identifying Hallmarks of the Disease and Optimal Treatment Strategies (2002) (0)
- HLA contributions to risk and protection for anti-centromere autoantibody-positive scleroderma (2018) (0)
- CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization. (2023) (0)
- Pregnancy in patients with systemic sclerosis (2014) (0)
- Scleroderma Associated Pulmonary Hypertension (2008) (0)
- Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States (2022) (0)
- Development of a composite index for clinical trials in early diffuse cutaneous systemic sclerosis - the combined response index in systemic sclerosis (2014) (0)
- OP0144 Intravenous versus oral cyclophosphamide (CYC) for the treatment of interstitial lung involvement (ILD) and skin involvement in systemic sclerosis (SSC): safety and efficacy evaluation in a large multi-centre scleroderma cohort (2018) (0)
- Abstract 15226: Right Heart Parameters for Prediction of Exercise Induced Pulmonary Hypertension in Patients With Systemic Sclerosis (2013) (0)
- Controversies and Consensus: Identifying the Key Issues in Exercise Testing (2008) (0)
- THE ASSOCIATION OF AUTOANTIBODIES WITH PULMONARY HYPERTENSION IN SCLERODERMA (2008) (0)
- Chapter 20 The Kidney in Systemic Sclerosis (2007) (0)
- Hospital readmission in systemic sclerosis associated pulmonary hypertension: Results from the PHAROS registry. (2021) (0)
- Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis (2023) (0)
- Exercise Right Heart Catheterization (RHC) Adds Important Information to a Resting RHC in Systemic Sclerosis (2011) (0)
- Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. (2023) (0)
- Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi‐center US‐based longitudinal registry (2021) (0)
- Proposal for the establishment of a connective tissue disease task force within the pulmonary vascular research institute (2009) (0)
- Baseline Differences in the Borderline vs Normal Pulmonary Hypertension: PHAROS (2010) (0)
- Dyspnea Assessment in Scleroderma Patients From PHAROS: Utility of the UCSD Shortness of Breath Questionnaire (2010) (0)
- Scleroderma in Pigmented Skin Populations (2018) (0)
- A Scleroderma Patient Inquires About Pregnancy (2011) (0)
- Pregnancy and Scleroderma (2020) (0)
- Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial (2022) (0)
- Long-Term Evaluation of Pulmonary Function Tests in Subgroups of Patients with Interstitial Pneumonia with Autoimmune Features (2019) (0)
- Comparative Studies in Systemic Sclerosis of Esophageal Function (1992) (0)
- Mental Health Considerations in Chronic Disease: What Is the Best Approach for Supporting a Scleroderma Patient? (2023) (0)
- Can Exercise Echocardiography Predict the Development of Pulmonary Hypertension in Systemic Sclerosis (2015) (0)
- Scleroderma Associated Interstitial Lung Disease (2020) (0)
- Agreement For Functional Class Assignment Among Pulmonary Hypertension Experts Using A Standardized Activities Questionnaire (2010) (0)
- Pulmonary Arterial Hypertension Associated With Scleroderma (2008) (0)
- Long-term evaluation of pulmonary function and survival of patients with interstitial pneumonia with autoimmune features. (2021) (0)
- Systemic Sclerosis 2011 (2012) (0)
- RETHINKING SURVIVAL IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: INSIGHTS FROM THE PHAROS REGISTRY (2022) (0)
- Systemic sclerosis. (1990) (0)
- Scleroderma Autoantibodies Predict the Type of Pulmonary Hypertension in PHAROS (2010) (0)
- Management of systemic sclerosis (2011) (0)
- AB1206-HPR Adaptation into spanish of the scleroderma health assesment questionnaire (S-HAQ) (2017) (0)
- Lessons from clinical trials in systemic sclerosis (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Virginia D. Steen?
Virginia D. Steen is affiliated with the following schools:
